Trends in industrialization of biotherapeutics: a survey of product characteristics of 89 antibody-based biotherapeutics.

ABSTRACT: There is considerable interest in the pharmaceutical industry toward development of antibody-based biotherapeutics because they can selectively bind diverse receptors and often possess desirable pharmacology. Here, we studied product characteristics of 89 marketed antibody-based biotherapeutics that were approved from 1986 to mid-2020 by gathering publicly available information. Our analyses revealed major trends in their emergence as the best-selling class of pharmaceuticals. Early on, most therapeutic monoclonal antibodies were developed to treat cancer, with CD20 being the most common target. Thanks to industrialization of antibody manufacturing technologies, their use has now blossomed to include 15 different therapeutic areas and nearly 60 targets, and the field is still growing! Drug

SUBMITTER: Martin KP 

PROVIDER: S-EPMC10072077 | biostudies-literature | 2023 Jan-Dec

REPOSITORIES: biostudies-literature